Unimed's Revenue Soars to 32.7 Million Tunisian Dinars in Q1 2024

During the first quarter of 2024, Unimed's pharmaceutical manufacturing unit saw its revenue climb to 32.7 million Tunisian dinars, marking an 11% increase compared to the same period in the previous year, when it stood at 29.4 million dinars.

This growth is primarily attributed to two key factors:

• A 66% surge in hospital market sales
• A 13% increase in pharmacy sales compared to 2023

In terms of production capacity, Unimed also recorded a significant increase, with over 51 million units produced by the end of March 2024.

As for investments made during this quarter, both intangible and tangible, they amounted to 217,000 Tunisian dinars.

Furthermore, the long-term debt value stands at 20 million dinars, while short-term debts amount to 25 million dinars. These short-term debts primarily consist of:

• Bank credit repayments due within a year, totaling 8.6 million dinars
• Management credits, totaling 16 million dinars
• Leasing credits, totaling 0.4 million dinars